New approaches for patients with advanced radioiodine-refractory thyroid cancer

doi:10.5306/wjco.v13.i1.9

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8337)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

643

WORD

216

HTML

5051

Figures (1-2)

308

Tables (1-4)

321

Sum=6539

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

323

Download

570

Sum=893

Publishing Process of This Article

Item

Count

Browse

307

Download

598

Sum=905

Jan 24, 2022 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Jan 24, 2022; 13(1): 9-27
Published online Jan 24, 2022. doi: 10.5306/wjco.v13.i1.9

Full Size Figure Download Figure

Figure 1 Major molecular signaling pathways involved in thyroid carcinogenesis and its most significant inhibitors.

Citation: Pitoia F, Jerkovich F, Trimboli P, Smulever A. New approaches for patients with advanced radioiodine-refractory thyroid cancer. World J Clin Oncol 2022; 13(1): 9-27
URL: https://www.wjgnet.com/2218-4333/full/v13/i1/9.htm
DOI: https://dx.doi.org/10.5306/wjco.v13.i1.9